CAR-T Meeting 2023 | Analysis of MRD status in patients with BCP-ALL treated with CAR-T therapy
Martijn Verbeek
• 9 Feb 2023
Martijn Verbeek, MSc, Erasmus University Medical Center, Rotterdam, The Netherlands, shares some insights into a poster presented at the 5th European CAR T-cell Meeting, which focused on the use of a novel automated tool to analyze measurable residual disease (MRD) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CAR-T therapy. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
